The first patient has been dosed in a still-recruiting Phase 1 clinical trial testing DA01, an investigational cell therapy for…
Articles by Marisa Wexler, MS
The use of antipsychotics by people with early Parkinson’s disease (PD) has fallen substantially since the U.S. Food and…
The U.S. Food and Drug Administration (FDA) has approved Medtronic‘s SenSight Directional Lead System, which offers both sensing and directional…
Treatment with Nuplazid (pimavanserin) can ease symptoms of Parkinson’s disease psychosis (PDP) for up to 10 weeks, and…
Treatment with a low dose of the immune-modulating medication sargramostim was well-tolerated and eased motor symptoms in a small clinical…
Limitations in functional abilities due to advanced Parkinson’s disease result in billions of dollars of lost economic value in…
Non-motor symptoms are major determinants of quality of life (QOL) for people with Parkinson’s disease who have undergone…
A new formulation of rasagiline, approved for Parkinson’s disease, may allow the therapy to be given by applying…
People with moderate or advanced Parkinson’s disease have abnormally low levels of caffeine in their saliva, despite normal caffeine…
Scientists have identified genetic variations that are associated with different rates of disease progression in people with Parkinson’s disease.